Cingulate Inc. (CING) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cingulate reported revenue of $0. Net income was -$22.4M, or -$4.44 per diluted share. Operating activities generated -$17.2M of cash, leaving -$17.4M of free cash flow. At fiscal year end, Cingulate held $15.1M in total assets against $12.6M in total liabilities, including $11.0M of cash and equivalents.
Open the full interactive Cingulate financials → Quarterly statements, key ratios, valuation history and price charts.
Cingulate Key Stats
| Share Price | $4.72 |
|---|---|
| Market Cap | $62.2M |
| 52-Week Range | $3.33 – $11.66 |
| Shares Outstanding | 13.2 million (basic, 2026 Q2) |
Cingulate Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$20.7M | -$17.5M | -$22.8M | -$15.6M | -$19.9M |
| Pre-Tax Income | -$20.7M | -$17.7M | -$23.5M | -$15.5M | -$22.4M |
| Net Income | -$20.7M | -$17.7M | -$23.5M | -$15.5M | -$22.4M |
| Diluted EPS | -$669.60 | — | -$312.00 | -$10.20 | -$4.44 |
Cingulate Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.3M | -$6.5M | -$9.3M | -$5.9M |
| Diluted EPS | -$1.35 | -$1.29 | -$0.95 | -$0.45 |
Cingulate Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $16.5M | $5.4M | $52,416 | $12.2M | $11.0M |
| Current Assets | $18.9M | $7.9M | $578,594 | $12.7M | $12.0M |
| Total Assets | $22.9M | $11.4M | $3.5M | $14.9M | $15.1M |
| Current Liabilities | $1.2M | $7.0M | $10.2M | $5.0M | $10.3M |
| Total Long-Term Debt | — | — | $5.1M | $5.0M | $7.4M |
| Total Liabilities | $2.0M | $7.5M | $10.4M | $7.4M | $12.6M |
| Shareholders' Equity | $20.8M | $3.9M | -$6.9M | $7.5M | $2.5M |
Cingulate Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$10.4M | -$15.9M | -$15.0M | -$18.5M | -$17.2M |
| Cash From Investing | -$814,736 | -$152,652 | -$224,096 | -$211,800 | -$162,138 |
| Cash From Financing | $26.5M | $4.9M | $10.0M | $30.8M | $16.1M |
| Free Cash Flow | -$11.2M | -$16.0M | -$15.3M | -$18.7M | -$17.4M |
Figures from Cingulate's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cingulate financials page for every line item.
Cingulate Company Profile
| Ticker | CING |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Kansas City, Kansas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001862150 |
Frequently Asked Questions
What was Cingulate's revenue in fiscal 2025?
Cingulate (CING) reported revenue of $0 for fiscal 2025.
What is Cingulate's annual revenue history?
Cingulate's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cingulate's net income in fiscal 2025?
Cingulate reported net income of -$22.4M for fiscal 2025.
What was Cingulate's earnings per share (EPS) in fiscal 2025?
Cingulate's diluted EPS was -$4.44 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cingulate generate in fiscal 2025?
Cingulate generated -$17.4M of free cash flow in fiscal 2025.
What was Cingulate's revenue last quarter?
In its most recent reported quarter (2026 Q2), Cingulate reported revenue of $0.
How much debt does Cingulate have?
Cingulate reported $7.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Cingulate are outstanding?
Cingulate reported a weighted average of 13.2 million basic shares outstanding in 2026 Q2.
What is Cingulate's market cap?
Based on its latest closing price, Cingulate (CING) has a market capitalization of about $62.2M.
When does Cingulate's fiscal year end?
Cingulate's fiscal year end, as registered with the SEC, is December 31.
Where is Cingulate headquartered?
Cingulate lists its business address in Kansas City, Kansas in its SEC filings.